Arcturus Gets Fed Award for Self-amplifying mRNA Vaccine for Rapid Pandemiclu Respon Fse

Arcturus will expand its current influenza vaccine program to include development of a pandemic influenza vaccine based on its proprietary self-amplifying mRNA platform with the support of the Biomedical Advanced Research and Development Authority

$63.2 Million base award to fund development from preclinical stage through Phase 1 over three-year period

A lower-dose, freeze-dried, pandemic influenza vaccine candidate will use Arcturus’ STARR™ self-amplifying mRNA vaccine platform technology which demonstrated favorable safety and efficacy against SARS-CoV-2 infection combined with a stable cold chain profile that may help support U.S. government pandemic preparedness goals

https://finance.yahoo.com/news/arcturus-announces-63-2-million-200000755.html